Nevanac

Alcon has launched Nevanac (nepafenac) for the prevention and treatment of post-operative pain and inflammation associated with cataract surgery.

Nevanac (nepafenac) is a topical NSAID for use in preventing and managing post-operative pain. Nepafenac is a prodrug, it penetrates the cornea and is converted to its active metabolite amfenac. Amfenac then inhibits the action of cyclooxygenase thereby inhibiting prostaglandin production.

Treatment should be started on the day before cataract surgery and continued for up to three weeks after surgery. Drops should be applied to the affected eye(s) three times daily with an additional drop 30-120 minutes prior to surgery.

As with other NSAIDs, nepafenac is contraindicated in patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDS.

View Nevanac drug record

Further information: Alcon

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...